Corcept Therapeutics Inc
For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders and has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease. In February 2012, the company introduced Korlym ®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous hypercortisolism. Corcept is headquartered in Redwood City, California.
Generated $672.0 in free cash flow for every $1 of capital expenditure in FY25.
Current Price
$51.42
+10.53%GoodMoat Value
$16.61
67.7% overvaluedCorcept Therapeutics Inc (CORT) Insider Trades
CORT Insider Trading Activity
Track insider trading transactions for Corcept Therapeutics Inc (CORT). Monitor recent buys, sells, and option exercises by officers, directors, and 10% beneficial owners. Insider trading activity can signal management confidence or concern about a stock's future prospects.
Current stock price: $51.42. Market cap: $5.47B. This page displays the most recent insider transactions for CORT, including the insider's name, title, transaction type (purchase, sale, or option exercise), number of shares, and total value. Filter transactions by type to focus on open-market purchases or sales.
Insider buying is often viewed as a bullish signal, as insiders are putting their own capital at risk. Conversely, large insider sales may warrant further investigation. Use GoodMoat's insider trading data alongside financial analysis, quality scores, and valuation tools for a comprehensive view of Corcept Therapeutics Inc's investment outlook.